Table of Contents
What changed
Revenue slipped 4.7% to NZ$7.9m, but the losses narrowed across the stack. EBITDA improved to -NZ$5.1m from -NZ$5.7m, while PBT loss narrowed 41.4% to -NZ$13.0m (FY22: -NZ$22.1m). NPAT showed a smaller 33.6% improvement because FY22 carried a NZ$2.6m tax benefit that FY23 did not repeat — PBT is the cleaner operating read.
Operating cash outflow halved to -NZ$5.6m from -NZ$11.6m, and capex was negligible at NZ$0.035m. Despite that improvement, cash on hand fell 83.0% to NZ$0.9m (FY22: NZ$5.4m). Gross borrowings edged up to NZ$12.4m, pushing net debt to roughly NZ$11.5m from NZ$6.9m. Total equity was cut almost exactly in half to NZ$11.9m.
Segment mix tilted further toward Honey, which now represents 73.8% of revenue (FY22: 60.7%) at NZ$5.8m. Sale-of-goods revenue fell to NZ$1.5m from NZ$3.3m, taking its share from 39.4% to 18.6%. Agency services remains a minor contributor at NZ$0.6m. All three segments were still EBITDA loss-making.
What matters
- Liquidity is the binding constraint. With NZ$0.9m cash, an FY23 pre-lease free cash outflow of -NZ$5.6m, and gross borrowings of NZ$12.4m, the rate of improvement in cash burn matters more than the P&L trajectory. At FY23's burn rate the current cash position is not self-sustaining.
- Equity has halved. Total equity fell to NZ$11.9m from NZ$24.1m, implying a funded loss absorption of roughly NZ$12.2m against the NZ$13.0m NPAT loss. ROE moved from -81.1% to -108.7%.
- Segment concentration has intensified. Honey is now nearly three-quarters of revenue but is still loss-making at the EBITDA level, and the release explicitly flags reliance on a Chinese-market customer. The branded Me Today sale-of-goods line effectively halved in revenue contribution.
Expectations
No quantified revenue or earnings target, and no forward-work balance, was disclosed. The company's narrative references strategy execution and sales opportunities without attaching figures to them.
On shape: HY23 delivered 45.7% of full-year revenue but 59.8% of the full-year EBITDA loss, meaning the second half was revenue-heavier but also carried a disproportionate share of the NPAT loss (44.7% of the year-on-year NPAT loss sits in H1, 55.3% in H2). On a segment basis, FY23 was marginally worse than FY22 in the Sale of Goods EBITDA result, and better in Honey and Agency. The release does not support a clear inflection claim.
Quality of result
The earnings improvement is real at the operating line — EBITDA loss narrowed by NZ$0.5m on NZ$0.4m lower revenue, implying some cost discipline — but a material share of the NPAT/PBT improvement is flattered by the FY22 base, which included non-cash items and a tax benefit that did not recur in FY23 (effective tax rate 0% vs 11.8%).
The operating cash flow improvement also warrants caution. Inventories fell by NZ$2.0m, providing a working-capital tailwind, while trade debtors jumped 81.8% to NZ$1.7m, lifting receivable days from 40 to 77 — a clear cash-conversion headwind that partially offset the inventory release. Inventory days remain extraordinarily high at roughly 684 days, so the balance-sheet release is from a very stretched starting point rather than genuine throughput improvement. Full working capital cannot be reconciled because payables detail was not in the extraction.
Pre-lease FCF of -NZ$5.6m against an NPAT loss of -NZ$13.0m reflects the large non-cash element in the P&L (fair value, impairment, restructuring references are cited but not quantified in extraction).
Unresolved
- What is the funding runway? With NZ$0.9m cash and ongoing operating outflows, the release does not quantify headroom under the bank loan and subordinated note, covenant position, or any planned capital raise.
- What is the quantum of restructuring, fair value and impairment adjustments in FY23 PBT, and how much of the year-on-year improvement is underlying versus base-effect?
- Why did receivable days nearly double? The release does not reconcile the NZ$0.7m debtor build to specific customers or terms.
- When does Honey reach EBITDA breakeven, given it is 74% of revenue and still -NZ$1.2m at the segment line?
- What is the realisable value of the NZ$14.8m inventory balance, given ~684 days on hand?
This briefing cannot assess going-concern status, covenant headroom, or any post-balance-date funding actions, because the extraction does not contain that disclosure.
Key metrics
| Metric | FY23 | FY22 | Change |
|---|---|---|---|
| Revenue | $7.9m | $8.3m | -4.7% ↓ |
| EBITDA | −$5.1m | −$5.7m | +9.0% ↑ |
| Net profit after tax | −$13.0m | −$19.5m | +33.6% ↑ |
| Net cash inflow from operating activities | −$5.6m | −$11.6m | +52.0% ↑ |
| Operating profit | −$7.4m | −$8.8m | +15.8% ↑ |
| Profit before tax | −$13.0m | −$22.1m | +41.4% ↑ |
| Cash and cash equivalents | $0.9m | $5.4m | -83.0% ↓ |
| Total assets | $26.9m | $39.5m | -31.7% ↓ |
Reference: annolyse.ai/briefings/mee-fy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Sale of goods | $1.5m | $3.3m | −$2.4m | -20.8pp |
| Agency services | $0.6m | $0.5m | −$0.2m | +1.2pp |
| Honey | $5.8m | $5.0m | −$1.2m | +13.1pp |
Reference: annolyse.ai/briefings/mee-fy23
Analytical metrics
| Metric | FY23 | FY22 | Context |
|---|---|---|---|
| OCF / EBITDA (cash conversion) | 107.9% | 204.9% | deteriorated |
| FCF pre-lease | −$5.6m | −$11.9m | +$6.3m |
| FCF / NPAT | 43.1% | 60.9% | complementary conversion metric |
| Capex % revenue | 0.4% | 3.9% | — |
| Capex | −$0.0m | −$0.3m | +$0.3m |
| Debtor days | 76.9 | 40.3 | +36.6 days |
| Inventory days | 683.5 | 740.9 | -57.4 days |
| Trade debtors | $1.7m | $0.9m | +$0.7m |
| Net debt | $11.5m | $6.9m | +$4.7m |
| Net debt / EBITDA | 2.20x | 1.20x | Weakening |
| Gross borrowings | $12.4m | $12.2m | +$0.2m |
| ROE (annualised) | -108.7% | -81.1% | Weakening |
| HY23 share of FY23 revenue | 45.7% | — | Other half was 54.3% |
| HY23 share of FY23 EBITDA | 59.8% | — | Other half was 40.2% |
| HY23 share of FY23 NPAT | 44.7% | — | Other half was 55.3% |
| Profit from continuing operations | — | −$19.5m | — |
Reference: annolyse.ai/briefings/mee-fy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.